Bristol-Myers Squibb Company (NYSE:BMY) stated gains of 1,087,489 shares or 6.6% in the short interest. The short interest registered from 16,416,544 on May 31,2016 to 17,504,033 on June 15,2016. In terms of floated shares, the shorted positions stood at 1%. The stock has been averaging 5,384,175 shares daily in trading and would need 3 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Bristol-Myers Squibb Company (NYSE:BMY): The stock opened at $70.75 on Friday but the bulls could not build on the opening and the stock topped out at $71.85 for the day. The stock traded down to $70.53 during the day, due to lack of any buying support eventually closed down at $70.61 with a loss of -2.79% for the day. The stock had closed at $72.64 on the previous day. The total traded volume was 7,414,129 shares.
The company shares have rallied 7.03% from its 1 Year high price. On Jun 6, 2016, the shares registered one year high at $75.12 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $71.78 and the 200 Day Moving Average price is recorded at $67.05.
Bristol-Myers Squibb Company (NYSE:BMY) has tumbled 0.08% during the past week and has dropped 0.98% in the last 4 week period. In the past week, the company has outperformed the S&P 500 by 1.57% and the outperformance has advanced to 2.01% for the last 4 weeks period.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.